Which treatment modality should we choose for advanced hepatocellular carcinoma?
نویسندگان
چکیده
منابع مشابه
Which treatment modality should we choose for advanced hepatocellular carcinoma?
The definition of 'advanced' hepatocellular carcinoma (HCC) has been vague and included various stages. This term has sometimes meant 'multinodular/unresectable HCC', 'HCC with vas-cular invasion', or 'HCC with extra-hepatic spread'. Since the introduction of the Barcelona Clinic Liver Cancer (BCLC) stage in 1999, the term 'advanced HCC' has been defined as a symptomatic tumor and/or invasive t...
متن کاملCapecitabine for treatment of advanced hepatocellular carcinoma.
BACKGROUND/AIMS Patients with advanced hepatocellular carcinoma (HCC) face a dismal prognosis, as no effective palliative chemotherapy exists. Moreover, treatment of patients with hepatocellular carcinoma presents a major challenge, because associated cirrhosis limits the choice of chemotherapeutic agents. We evaluated the activity and toxicity of capecitabine in patients with advanced hepatoce...
متن کاملPreclinical studies of 166Ho-chitosan for treatment of hepatocellular carcinoma
Introduction: Recently, due to the special characteristics of 166Ho and chitosan, 166Ho-chitosan complex was developed for treatment of tumors such as hepatocellular carcinoma. This complex has been lately prepared with high radiochemical purity in our lab. The preclinical studies of the complex however should be performed to evaluate the tracer concentration in target and...
متن کاملTreatment of Stage IVA Hepatocellular Carcinoma Should
Main Outcome Measures: Intraoperative data, recurrence, and long-term survival rates were analyzed. Results: Postoperative mortality and morbidity were 5% and 30%, respectively. The median number of resected tumors per patient was 3, and the median diameter of the largest tumor was 60 mm. With a median follow-up of 23 months, 14 patients (70%) developed recurrence. Treatment of recurrence was p...
متن کاملSystemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?
Worldwide, hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related death. In the U.S., 18,510 new cancers of the liver and intrahepatic bile duct are expected in 2006, with an estimated 16,200 deaths. The incidence rates for HCC in the U.S. continued to rise steadily through 1998 and doubled during the period 1975-1995. Unresectable or me...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Korean Journal of Hepatology
سال: 2010
ISSN: 1738-222X
DOI: 10.3350/kjhep.2010.16.4.353